Second medical use patents

Patent cliffs remain one of the biggest issues facing the pharmaceutical industry. In 2012 and 2013, a number of high-value branded drugs have lost or will lose their patent protection (for example Sanofi and Bristol-Myers’ Plavix, Novartis’ Diovan, Eli Lilly’s Cymbalta, Novartis’ Reclast and Merck’s Propacae). The resultant erosion
of earnings is vast.

In the light of this, originators’ ability to extend the patent life of their medicines through securing good secondary patents (composition patents, patents for new polymorphs/formulations, synthesis patents and patents for new therapeutic uses) is key.

‘Second medical use’ patents (new therapeutic uses for known active ingredients) are an important component of the potential second-line patent protection. In the UK, patentability of a second medical use was confirmed by the Court of Appeal decision in Actavis v Merck…

If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.

Sign in or Register to continue reading this article

Sign in


It's quick, easy and free!

It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.

Register now

Why register to The Lawyer


Industry insight

In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.


Market intelligence

Identify the major players and business opportunities within a particular region through our series of free, special reports.


Email newsletters

Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.

More relevant to you

To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.

Analysis from The Lawyer

  • Panel reviews

    Panel reviews 2014: The chosen ones

    Which firms are cutting it in this era of slimline rosters, and who are the GC new brooms making clean sweeps? The Lawyer can reveal all

  • training

    Accutrainee: Revolution postponed

    At the time of its launch Accutrainee was described as a revolutionary change to the training model. Has it proved to be so? Not really.

View more analysis from The Lawyer


One Bishops Square
E1 6AD

Turnover (£m): 1,234.30
No. of lawyers: 2,194 (UK 200)
Jurisdiction: UK
No. of offices: 11
No. of qualified lawyers: 369 (International 50)
No. of partners: 81